trial · primary record
Intravitreal Adalimumab
Retinitis Pigmentosa (RP)
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2027-08-01 |
| Primary endpoint | Change in Field Preservation Deviation Index (FPDI) |
| Registry ID | NCT07348588 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:39.712Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07348588
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.